publication venue for
- Elimination of vaso-occlusive crises after exagamglogene autotemcel in patients with severe Sickle Cell Disease 2023
- Phase I study of the LSD1 inhibitor tranylcypromine (TCP) in combination with all-trans retinoic acid (ATRA) and low-dose cytarabine (LDAC) in elderly, medically non-fit patients with AML or high-risk MDS (TRANSATRA trial) 2023
- Systemic treatment of cholangiocellular carcinoma in Germany - Results from the prospective national intersectoral cohort study JADE 2023
- Sustained effect on hemoglobin levels and reduced transfusion burden maintained in patients with pyruvate kinase deficiency on mitapivat in a long-term extension study 2022
- ACTIVATE: A phase 3, randomized, multicenter, double-blind, placebo-controlled study of mitapivat in adults with Pyruvate kinase deficiency who are not regularly transfused 2021
- Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel 2020
- Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial 2020
- FRACTION-RCC: innovative, high-throughput assessment of nivolumab plus ipilimumab (N plus I) for treatment-refractory advanced renal cell carcinoma (aRCC) 2020
- Comparison of leukemia-associated immunophenotype (LAIP)-based and different-from-normal (DfN)-based analysis of measurable residual disease (MRD) in patients with AML 2019
- Prognostic impact of minimal residual disease on outcome in the SORMAIN trial 2019
- Reduced-intensity conditioning regimen with fludarabine/melphalan versus sequential melphalan, fludarabine and total body irradiation conditioning in acute myeloid leukemia patients with active leukemia or measurable residual disease 2019
- Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL) 2019
- Flow cytometric assessment of minimal residual disease in AML: National harmonization in the HARMONIZE initiative 2018
- An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) 2018
- Haploidentical versus matched unrelated donor myeloablative allogeneic stem cell transplantation for patients with high-risk acute leukemia: a single-center donor comparison. 2018
- Defining minimal residual disease by flow cytometry in acute myeloid leukemia: the HARMONIZE initiative 2017
- The histone demethylase LSD1/KDM1A as therapeutic target in AML 2017
- Long-term results of mTOR-inhibitor-based therapy in severe sclerodermatous chronic GvHD 2016
- Outcome of allogeneic stem cell transplantation for patients with high-risk acute leukemia according to donor and graft versus-host disease prophylaxis 2016
- LSD1 inhibition induces differentiation in murine models of AML 2015
- Multi-molecular complexes of Bcl-2 proteins regulate membrane permeabilization by Bax 2015
- Conformation dictates function: Membrane associated interactions of Bcl-XL with Bax, c(t) Bid and Bad 2014